Abstract
Introduction

Crohn's disease (CD) and ulcerative colitis (UC) are the two main forms of inflammatory bowel disease (IBD). IBD occurs in clinically immunocompetent individuals and its characteristic symptoms arise from an aggressive, cytokine-driven non-infectious inflammation of the gut. In particular, T cells and antigen-presenting cells produce pro-inflammatory cytokines, including interleukin (IL)-6 and tumour necrosis factor (TNF)-␣ that cause mucosal inflammation and destruction
. [4, 5] . EBA is a rare disease with an estimated incidence of 0.19-0.26 new cases/million inhabitants/year [6] [7] [8] [9] . Autoantibodies against type VII collagen are also responsible for the skin blistering in a subgroup of patients with systemic lupus erythematosus [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . [20] , as well as cryoglobulinemia [21] and psoriasis [22] [23] [24] .
Epidermolysis bullosa acquisita (EBA) is a prototypical organspecific autoimmune disease characterized by blistering of the skin and mucous membranes caused by autoantibodies specific to type VII collagen of the dermal-epidermal junction
Occasionally, EBA is associated with further autoimmune diseases, including rheumatoid arthritis and diabetes mellitus
A remarkable and intriguing association exists between autoimmunity against type VII collagen and IBD. Although CD has been described in approximately 30% of EBA patients [20, 25] , autoantibodies against type VII collagen have been found in up to 68% of CD patients [25] . UC also associates with autoantibodies against type VII collagen, although with a lower frequency when compared with CD, and, in rare instants, with clinically overt EBA [25, 26] .
In the present review article we examine the association of IBD with autoimmunity against type VII collagen. Fig. 1) [5] . Type VII collagen is expressed in the basement membranes of stratified squamous epithelia, including the skin, oesophagus, [25, 27] , oral and anal mucosa [28, 29] (Fig. 1) . In addition, the balance of evidence argues for the presence of collagen VII also in the colonic epithelium [25, 27, 28] . However, its expression is clearly higher in skin and mucous membranes compared to the intestine [30, 31] . Type (Fig. 4) [59] . The situation is compounded by the fact that no animal model of CD or UC accurately reproduces all the features described in human diseases [61] [62] [63] [64] [65] [66] [67] .
The autoantigen: type VII collagen
Type VII collagen is an extracellular matrix protein and, among other skin proteins, is a major target of autoantibodies in autoimmune bullous diseases (
Although mainly affecting the gut, IBD are systemic conditions and frequently show extraintestinal manifestations, commonly affecting the joints, eyes and skin [68, 69] . The reasons why particular organs/tissues are preferentially affected and why only some of these manifestations are linked to the evolution of IBD remain unclear.
Autoimmune phenomena in IBD
Autoimmune phenomena include serum and mucosal autoantibodies against intestinal epithelial cells/epithelial antigens both in CD and UC [54] , pancreatic proteins [70] , cardiolipin [71] , cytoskeletal proteins [72] , as well as pANCA [73] [74] [75] and ASCA [76] . In addition, circulating complement-fixing immune complexes have been demonstrated in serum of patients with CD and UC [77, 78] . Furthermore, deposits of activated complement in the mucosal microvessels and in the intestinal epithelium associated with IgG1 antibodies have been described in IBD patients [79] .
Importantly, while infectious agents can induce/activate autoreactive T cells [80] , specific inflammatory signals may also induce gut-specific autoimmunity [81] . Collectively, these lines of evidence suggest that the autoimmune phenomena in IBD may be triggered by pathogens lacking homology to self-proteins. [82] [83] [84] [85] [86] [87] [88] . Cutaneous manifestations occur frequently in IBD with an incidence of up to 40% [82] .The most common dermatological conditions associated with IBD include erythema nodosum and pyoderma gangrenosum [89] [90] [91] [92] [93] [94] [95] [96] [97] . Among the autoimmune dermatoses, psoriasis and EBA are the conditions most frequently associated with IBD [94, 98] . Although relatively uncommon in patients with IBD, EBA was considered as a longterm complication of CD in early publications [96, 97, 99] . [102] . In contrast, mainly because of the rarity of EBA, the genetic factors associated with disease susceptibility were poorly studied [103, 104] (Table S1) shows that in the majority of cases, the onset of the gastrointestinal symptoms precedes or occurs simultaneously with the skin blistering disease [25, 26, 99, [107] [108] [109] [110] [111] [112] [113] . Less frequently, the diagnosis of IBD follows the development of skin blistering [40, [114] [115] [116] [117] [118] [119] 
Association of IBD with autoimmune diseases
IBD is frequently associated with several (systemic) autoimmune diseases, including primary sclerosing cholangitis, rheumatoid arthritis, various vasculitis forms, autoimmune hepatitis and pancreatitis
Autoimmunity to type VII collagen in IBD
Sequence of occurrence of skin blistering and bowel disease in IBD associated with EBA
Analysis of the reports of EBA associated with IBD
. It is conceivable that in some patients, milder gastrointestinal symptoms were overlooked or misdiagnosed as habitual diarrhoea or irritable bowel syndrome. We therefore favour the hypothesis, that chronic, but occasionally subclinical inflammation of the gut, precedes the development of EBA in all patients. Systematic and thorough evaluation of EBA patients for gastrointestinal symptoms and intestinal lesions, including the histopathological analysis of mucosa biopsies, in the future will certainly provide a clear answer to this question.
Initiation of the type VII collagenspecific autoimmune response in IBD
Response of EBA and IBD to treatment
The treatment of EBA is notoriously difficult [124, 125] [126] , colchicine [127] [128] [129] [130] [131] , cyclosporine [132, 133] , mycophenolate mofetil [134] and azathioprine. In addition, the removal of autoantibodies from circulation by immunoadsorption is a rationale approach that reportedly improved the clinical condition [135] . More recently, biological response modulators such as the anti-CD20 mAb rituximab have been shown to be effective in several EBA patients [135] [136] [137] [138] .
Current treatment options and therapeutic prospectives in IBD have been reviewed in detail recently [139] . The classic treatment of IBD includes mesalamine [140, 141] for UC as first line treatment. In addition, immunosuppressive agents (corticosteroids [142] , azathioprine [143] , 6-mercaptopurine [143, 144] , methotrexate [145, 146] and less cyclosporine [147] (Fig. 3) 
; (iii ) An associated EBA should be excluded in patients with CD showing lesions of oral and oesophageal mucosa and (iv ) For the treatment of the blistering skin disease associated with IBD, the multidisciplinary team including dermatologists, should consider as adjunct therapeutic option the removal of autoantibodies against type VII collagen by immunoapheresis/leukapheresis and/or targeted depletion of autoreactive B cells (e.g. rituximab).
Concluding remarks and perspectives
